n Sensitivity Specificity True positive rate True negative rate Accuracy p
Total   226 19.5% 95.0% 91.7% 34.5% 42.8% <0.0001
T 1a 69 7.2% 95.0% 55.6% 60.0% 30.9% 0.4868 (n.s.)
  1b 54 9.3% 95.0% 55.6% 66.2% 30.9% 0.2763 (n.s.)
  2a 57 28.1% 95.0% 80.0% 70.1% 34.3% <0.0001
  2b 19 36.8% 95.0% 63.6% 88.9% 31.5% <0.0001
  3 22 45.5% 95.0% 71.4% 88.9% 32.4% <0.0001
  4 5 20.0% 95.0% 20.0% 96.0% 29.7% 0.2147 (n.s.)
N 0 168 14.3% 95.0% 85.7% 40.0% 36.7% 0.0068
  1 12 41.7% 95.0% 55.6% 93.2% 30.9% <0.0001
  2 36 30.6% 95.0% 73.3% 79.3% 32.7% <0.0001
  3 10 40.0% 95.0% 50.0% 94.1% 30.6% 0.0019
M 0 210 17.1% 95.0% 90.0% 35.6% 40.4% 0.0029
  1a 6 50.0% 95.0% 42.9% 97.0% 30.3% <0.0001
  1b 10 50.0% 95.0% 55.6% 95.0% 30.9% <0.0001
Stage IA 103 6.8% 95.0% 63.6% 50.0% 31.5% 0.5375 (n.s.)
  IB 34 20.6% 95.0% 63.6% 78.0% 31.5% 0.0052
  IIA 19 21.1% 95.0% 50.0% 86.5% 30.6% 0.0201
  IIB 14 50.0% 95.0% 63.6% 93.2% 31.5% <0.0001
  IIIA 25 24.0% 95.0% 60.0% 83.5% 31.2% 0.0039
  IIIB 15 33.3% 95.0% 55.6% 90.6% 30.9% 0.0016
  IV 16 50.0% 95.0% 66.7% 92.3% 31.8% <0.0001
Table 3: Diagnostic properties of serum KL-6 levels in primary lung cancer.